• BMS’ CAR T therapy Abecma moves closer toward EU approval pharmatimes
    June 29, 2021
    Bristol Myers Squibb’s (BMS) CAR T cell therapy Abecma has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending its approval for the treatment of relapsed and ...
  • Ide-cel provides lasting remissions in multiply-relapsed myeloma europeanpharmaceuticalreview
    February 26, 2021
    BMS and bluebird bio have applied to the FDA for approval of ide-cel as a standard therapy for relapsed or refractory multiple myeloma based on positive Phase II trial results.
PharmaSources Customer Service